• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Pharmacokinetics of intravenous and oral losartan in patients with heart failure.
【24h】

Pharmacokinetics of intravenous and oral losartan in patients with heart failure.

机译：心力衰竭患者静脉和口服氯沙坦的药代动力学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The pharmacokinetics of a selective AT1-subtype, nonpeptide, orally active, angiotensin II receptor antagonist, losartan, were characterized in 11 patients with heart failure (New York Heart Association class II, n = 6; class III, n = 4; class IV, n = 1) after oral and intravenous administration. In these patients, average plasma clearance of losartan was 566 mL/min, volume of distribution at steady-state was 34 L, and terminal plasma half-life was 1.5 hours. Average bioavailability was 36%. No clinically significant accumulation of losartan or its active metabolite, EXP3174, occurred after multiple-dose oral administration for 7 to 8 days. Terminal plasma half-life of EXP3174 after oral administration of losartan was 7.6 hours. The pharmacokinetics of losartan in patients in this study appear to be similar to those in healthy subjects studied previously.
机译：选择性AT1亚型，非肽，口服活性，血管紧张素II受体拮抗剂洛沙坦的药代动力学在11例心力衰竭患者中得到了表征（纽约心脏协会II级，n = 6; III级，n = 4; IV级，n = 1）口服和静脉内给药后。在这些患者中，氯沙坦的平均血浆清除率为566 mL / min，稳态时的分布体积为34 L，终末血浆半衰期为1.5小时。平均生物利用度为36％。口服7到8天后，氯沙坦或其活性代谢物EXP3174在临床上没有明显的积累。口服氯沙坦后EXP3174的血浆终末半衰期为7.6小时。氯沙坦在该研究患者中的药代动力学似乎与先前研究的健康受试者相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号